-$0.84 Earnings Per Share Expected for Aerie Pharmaceuticals, Inc. (AERI) This Quarter

Equities analysts forecast that Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) will post earnings of ($0.84) per share for the current fiscal quarter, Zacks reports. Zero analysts have issued estimates for Aerie Pharmaceuticals’ earnings. Aerie Pharmaceuticals posted earnings of ($0.87) per share in the same quarter last year, which would suggest a positive year-over-year growth rate of 3.4%. The company is scheduled to report its next earnings report after the market closes on Tuesday, August 1st.

On average, analysts expect that Aerie Pharmaceuticals will report full year earnings of ($3.13) per share for the current year, with EPS estimates ranging from ($3.26) to ($2.99). For the next fiscal year, analysts forecast that the business will post earnings of ($2.60) per share, with EPS estimates ranging from ($2.94) to ($2.10). Zacks’ EPS calculations are a mean average based on a survey of research analysts that follow Aerie Pharmaceuticals.

Aerie Pharmaceuticals (NASDAQ:AERI) last released its quarterly earnings data on Tuesday, May 2nd. The company reported ($0.76) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.74) by $0.02.

A number of research analysts recently commented on the company. Zacks Investment Research raised Aerie Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $66.00 target price on the stock in a research note on Monday, July 24th. BidaskClub raised Aerie Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Monday, July 24th. Stifel Nicolaus restated a “buy” rating on shares of Aerie Pharmaceuticals in a research report on Friday, May 26th. Cowen and Company set a $100.00 price target on shares of Aerie Pharmaceuticals and gave the company a “buy” rating in a research report on Friday, May 26th. Finally, ValuEngine upgraded shares of Aerie Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $66.08.

Aerie Pharmaceuticals (AERI) traded down 2.16% during midday trading on Monday, hitting $54.30. The company had a trading volume of 256,447 shares. Aerie Pharmaceuticals has a 52 week low of $16.61 and a 52 week high of $59.50. The firm’s market capitalization is $1.83 billion. The firm’s 50 day moving average is $54.19 and its 200-day moving average is $47.38.

WARNING: “-$0.84 Earnings Per Share Expected for Aerie Pharmaceuticals, Inc. (AERI) This Quarter” was reported by Community Financial News and is owned by of Community Financial News. If you are reading this piece of content on another site, it was copied illegally and republished in violation of US & international trademark & copyright law. The correct version of this piece of content can be viewed at https://www.com-unik.info/2017/08/19/0-84-earnings-per-share-expected-for-aerie-pharmaceuticals-inc-aeri-this-quarter-updated-updated.html.

In other Aerie Pharmaceuticals news, major shareholder Foresite Capital Fund Ii, L.P. sold 20,000 shares of the firm’s stock in a transaction dated Friday, May 26th. The shares were sold at an average price of $55.95, for a total value of $1,119,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 9.36% of the company’s stock.

Several institutional investors have recently made changes to their positions in the stock. Quantbot Technologies LP acquired a new position in shares of Aerie Pharmaceuticals during the first quarter worth $107,000. Ameritas Investment Partners Inc. acquired a new position in shares of Aerie Pharmaceuticals during the first quarter worth $108,000. Federated Investors Inc. PA increased its position in shares of Aerie Pharmaceuticals by 88.7% in the fourth quarter. Federated Investors Inc. PA now owns 4,447 shares of the company’s stock worth $168,000 after buying an additional 2,090 shares in the last quarter. BlueCrest Capital Management Ltd acquired a new position in shares of Aerie Pharmaceuticals during the first quarter worth $202,000. Finally, Karp Capital Management Corp acquired a new position in shares of Aerie Pharmaceuticals during the first quarter worth $213,000. 92.60% of the stock is owned by institutional investors and hedge funds.

About Aerie Pharmaceuticals

Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).

Get a free copy of the Zacks research report on Aerie Pharmaceuticals (AERI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

What are top analysts saying about Aerie Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Aerie Pharmaceuticals Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit